Novartis Ag v. Ranbaxy Laboratories Ltd.

In the high-stakes world of pharmaceuticals, the line between genuine innovation and clever repackaging can mean billions of dollars. When a multinational drugmaker attempts to extend the life of a blockbuster medicine by patenting a new physical form of the same compound, the legal system is forced to ask a critical question: is this real progress, or just a strategic workaround? The clash between Novartis AG and Ranbaxy Laboratories Ltd. became a defining moment in answering that question, and it sent a powerful message to every founder and IP strategist watching the pharmaceutical industry.

Novartis AG, a global pharmaceutical powerhouse, filed a patent application seeking protection for a specific crystalline form—known as the ß-crystal—of imatinib mesylate, a compound used in cancer treatment. Standing in opposition was Ranbaxy Laboratories Ltd., represented through the legal counsel of Lakshmi Kumaran & Sridharan, which challenged the patentability of this new form. The dispute centered on whether this crystalline variant represented a genuine, patent-worthy invention or was simply a repackaged version of an already known substance. The opposition set the stage for a landmark examination of what qualifies as a true innovation under Indian patent law.

Novartis argued that the ß-crystal form of imatinib mesylate was a novel and non-obvious invention deserving of patent protection. On the opposing side, Ranbaxy contended that the invention was anticipated by prior art—meaning the substance or its properties were already known—and therefore lacked the novelty required for a patent. More critically, Ranbaxy challenged the application under Section 3(d) of the Patents Act, 1970, which specifically bars the patenting of new forms of known substances unless they demonstrate significantly enhanced efficacy. The legal friction boiled down to a fundamental clash: Novartis's claim of innovation versus Ranbaxy's assertion that this was merely a new form of an existing drug, without any proven therapeutic advantage.

The Tribunal ruled in favor of Ranbaxy Laboratories Ltd., refusing to grant Novartis the patent. The court found that the ß-crystal form of imatinib mesylate was anticipated by prior art and therefore lacked the novelty necessary for patentability. Even more decisively, the Tribunal held that the invention failed to demonstrate enhanced efficacy as mandated under Section 3(d) of the Patents Act, 1970. This provision exists specifically to prevent the practice of evergreening—where companies make minor modifications to existing drugs to extend their patent monopolies. The outcome was a clear signal that Indian patent law demands more than a new physical form; it demands a meaningful therapeutic improvement.

For founders, startup leaders, and IP professionals, this case delivers a hard-earned lesson: in India's patent landscape, a new salt, polymorph, or crystalline form of an already known substance will not pass muster unless you can prove it delivers significantly enhanced efficacy. Section 3(d) is not a technicality—it is a deliberate gatekeeper against patent evergreening. Before investing in patent applications for modified versions of existing compounds, businesses must rigorously evaluate whether their innovation offers a demonstrable, substantial therapeutic advantage. Otherwise, even the most well-funded patent strategy can crumble before the Tribunal.